Research Type: Policy Paper

Unsupported Price Increases Occurring in 2020

Nov 2021 | Policy Paper

The price of many existing drugs, both brand and generic, can increase substantially over time, and questions are frequently raised regarding whether these price increases are justified. State policymakers have been particularly active in seeking measures to address this issue. For example, both California and Vermont now have laws tracking substantial drug price increases, requiring drug manufacturers […]

Alternative Policies for Pricing Novel Vaccines and Drug Therapies for COVID-19

Jul 2020 | Policy Paper

ICER’s white paper provides a brief overview of approaches to manage the pricing of novel vaccines and treatments in times of public health emergencies. After summarizing the experiences and lessons learned from previous epidemics and the annual flu vaccine, the paper analyzes the potential advantages and disadvantages of six alternative approaches to pricing that policymakers from […]

Cornerstones of ‘Fair’ Drug Coverage

Sep 2020 | Policy Paper

The purpose of the white paper is to analyze the ethical and practical dimensions of insurance coverage policy, while presenting a corresponding set of criteria that will support a more transparent discussion among all health care stakeholders about whether specific cost sharing and utilization management policies are delivering “fair” patient access to prescription drugs. Date […]

Indication-specific pricing: pharmaceuticals in the United States health care system 

Dec 2015 | Policy Paper

The 2015 ICER Policy Summit convened an influential group of evidence policy leaders from insurers, pharmacy benefit management firms, and life science companies to discuss indication-specific pricing (ISP) of biopharmaceuticals and to explore the opportunities and challenges of ISP in the US health care system. Date of review: December 2015 For more information, please contact […]

Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value 

Dec 2016 | Policy Paper

This white paper was developed following a December 2016 meeting of ICER’s membership program, during which leaders from 20 payer and manufacturer organizations convened to share their perspectives on the future of gene therapy. The paper explores the scientific frontier being opened up by emerging gene therapies, with the potential for curing or substantially improving the […]

Methods Update: Value Assessment Framework

Jan 2020 | Policy Paper

In January 2020, ICER issued an update to the framework that underpins our evidence reports on new drugs and other health care interventions. ICER’s value framework is the product of more than 10 years’ experience working with all participants in the health care system to develop methods to assess the comparative clinical effectiveness and the […]

Unsupported Price Increases Occurring in 2017-2018

Oct 2019 | Policy Paper

ICER evaluated selected high-impact drugs with substantial price increases. ICER reviewed changes in the evidence base for each of these drugs and assess whether or not new clinical data exists that could suggest that the drugs could be significantly more beneficial for patients than what was previously understood. ICER published the final draft of its […]

Unsupported Price Increases Occurring in 2019

Jan 2021 | Policy Paper

On January 12, 2021, ICER published our latest report on Unsupported Price Increases (UPI) of prescription drugs in the United States. Among the top drugs with price increases in 2019 that had substantial effects on US spending, ICER determined that seven of 10 lacked adequate new evidence to demonstrate a substantial clinical benefit that was not […]

Methods Update: Treatments for Ultra-Rare Diseases

May 2017 | Policy Paper

ICER hosted a multi-stakeholder policy summit to discuss methods for assessing the value of new drugs for rare conditions. The summit included discussion of how these methods can be applied to recommend fair prices that reflect the value of orphan drugs to patients and the health system to allow for broader insurance coverage for innovative […]